Work

Database of Genomic Biomarkers for Cancer Drugs and Clinical Targetability in Solid Tumors

Year: 2015

Type: article

Abstract: SUMMARY: Comprehensive genomic profiling is expected to revolutionize cancer therapy. In this Prospective, we present the prevalence of mutations and copy-number alterations with predictive associations across solid tumors at different levels of stringency for gene-drug targetability. More than 90% of The Cancer Genome Atlas samples have potentially targetable alterations, the majority with multiple events, illustrating the challenges for treatment prioritization given the complexity of the genomic landscape. Nearly 80% of the variants in rarely mutated oncogenes are of uncertain functional significance, reflecting the gap in our understanding of the relevance of many alterations potentially linked to therapeutic actions. Access to targeted agents in early clinical trials could affect treatment decision in 75% of patients with cancer. Prospective implementation of large-scale molecular profiling and standardized reports of predictive biomarkers are fundamental steps for making precision cancer medicine a reality.

Source: Cancer Discovery

DOI: 10.1158/2159-8290.cd-14-1118

Authors: Rodrigo Dienstmann, In Sock Jang, Brian Bot, Stephen Friend, Justin Guinney

Institutions: Sage Bionetworks, Fred Hutch Cancer Center

Language: English

Topic: Cancer Genomics and Diagnostics

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Human Genome Research Institute, National Cancer Institute